Dana Cruse
Family · Parkersburg, WVNPI 1932482874
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,342 of the $108,759 with a category attached, or 61.0%. 27 manufacturers reported payments, led by Novo Nordisk at 44.4% of the total. 2025 is the largest year on record at $38,510, 2.9 times the $13,400 reported in 2021. Among family clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,009 payments — averaging $107.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$48K
- Corcept Therapeutics$28K
- Mannkind Corporation$13K
- AstraZeneca$4K
- Medtronic$4K
- Cequr Corporation$3K
- plus $9K from 21 others
What the payments were for
- Consulting fees$2,3402%
- Speaking & faculty fees$66,34261%
- Travel & lodging$18,54317%
- Food & beverage$21,42520%
- Education$490%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 239 | $48,237 |
| Corcept Therapeutics | 143 | $27,575 |
| Mannkind Corporation | 146 | $12,571 |
| AstraZeneca | 112 | $4,450 |
| Medtronic | 40 | $4,284 |
| Cequr Corporation | 5 | $2,809 |
| Ascensia Diabetes Care US Inc. | 5 | $2,046 |
| Sanofi-aventis U.S. LLC | 34 | $1,276 |
| Lilly USA, LLC | 76 | $1,226 |
| Insulet Corporation | 31 | $955 |
| Abbott | 58 | $856 |
| Boehringer Ingelheim | 33 | $544 |
| Merck | 24 | $370 |
| Bayer | 8 | $303 |
| Dexcom, Inc. | 10 | $257 |
| Xeris Pharmaceuticals, Inc. | 8 | $189 |
| Tandem Diabetes Care, Inc. | 8 | $154 |
| Kowa Pharmaceuticals America, Inc. | 8 | $140 |
| Ironshore Pharmaceuticals Inc. | 1 | $111 |
| Zealand Pharma US, Inc. | 5 | $93 |
| Recordati_rare_diseases_inc. | 4 | $74 |
| Sequel Med Tech, LLC | 3 | $68 |
| BETA Bionics, Inc. | 2 | $64 |
| AbbVie | 2 | $39 |
| Averitas Pharma Inc. | 2 | $35 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,759 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 13 | $561,439 |
| OzempicSemaglutide | 289 | $341,644 |
| JardianceEmpagliflozin | 130 | $104,671 |
| TrulicityDulaglutide | 88 | $97,048 |
| FarxigaDapagliflozin Propanediol | 85 | $70,924 |
| MounjaroTirzepatide | 37 | $41,671 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 23 | $11,518 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $9,572 |
| NovologInsulin Aspart | 27 | $7,322 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $6,868 |
| Pioglitazone Hcl | 346 | $2,499 |
| HumalogInsulin Lispro | 11 | $1,556 |
| Metformin Hcl ErMetformin Hcl | 31 | $238 |
| Metformin Hcl | 17 | $89 |
| Dexamethasone | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $27,575 | $561,43913 claims |
| Novo NordiskOzempic, Novolog | $48,237 | $348,966316 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,226 | $140,276136 claims |
| Boehringer IngelheimJardiance | $544 | $104,671130 claims |
| AstraZenecaFarxiga | $4,450 | $70,92485 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Parkersburg
- Jeannie GoffParkersburg$7K
- Ashley ComerCharleston$213K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
- Misty BareboHuntington$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.